102 related articles for article (PubMed ID: 7657850)
1. A bioequivalence study of oral controlled-release morphine using naltrexone blockade.
Kaiko RF; Grandy RP; Reder RF; Goldenheim PD; Sackler RS
J Clin Pharmacol; 1995 May; 35(5):499-504. PubMed ID: 7657850
[TBL] [Abstract][Full Text] [Related]
2. The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects.
Kaiko RF; Grandy RP; Oshlack B; Pav J; Horodniak J; Thomas G; Ingber E; Goldenheim PD
Cancer; 1989 Jun; 63(11 Suppl):2348-54. PubMed ID: 2720580
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade.
Bashaw ED; Kaiko RF; Grandy RP; Reder RF; Goldenheim PD
Int J Clin Pharmacol Ther; 1995 Sep; 33(9):524-9. PubMed ID: 8520812
[TBL] [Abstract][Full Text] [Related]
4. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
Thirlwell MP; Sloan PA; Maroun JA; Boos GJ; Besner JG; Stewart JH; Mount BM
Cancer; 1989 Jun; 63(11 Suppl):2275-83. PubMed ID: 2720576
[TBL] [Abstract][Full Text] [Related]
6. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Kinzler ER; Pantaleon C; Aigner S
Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
[TBL] [Abstract][Full Text] [Related]
7. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
8. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
9. The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets.
Kaiko RF; Fitzmartin RD; Thomas GB; Goldenheim PD
Pharmacotherapy; 1992; 12(2):107-13. PubMed ID: 1570227
[TBL] [Abstract][Full Text] [Related]
10. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
Gourlay GK
Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
12. Study of the bioequivalence of two controlled-release formulations of morphine.
Bourget P; Lesne-Hulin A; Quinquis-Desmaris V
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):588-94. PubMed ID: 8688982
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet.
Dayno JM; Niebler G; Lawler J; Elhauge T; Lindhardt K
J Opioid Manag; 2017; 13(2):111-124. PubMed ID: 28829526
[TBL] [Abstract][Full Text] [Related]
14. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
15. Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food.
Kaiko RF; Lazarus H; Cronin C; Grandy R; Thomas G; Goldenheim P
Hosp J; 1990; 6(4):17-30. PubMed ID: 2088996
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults.
Hunt TL; Kaiko RF
Clin Ther; 1991; 13(4):482-8. PubMed ID: 1934000
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
18. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (ORAMORPH SR) after multiple doses.
Bass J; Shepard KV; Lee JW; Hulse J
J Clin Pharmacol; 1992 Nov; 32(11):1003-7. PubMed ID: 1474160
[TBL] [Abstract][Full Text] [Related]
20. Formulation development of morphine sulfate sustained-release tablets and its bioequivalence study in healthy Thai volunteers.
Preechagoon D; Sumyai V; Chulavatnatol S; Kulvanich P; Tessiri T; Tontisirin K; Pongjanyakul T; Uchaipichat V; Aumpon S; Wongvipaporn C
AAPS PharmSciTech; 2010 Sep; 11(3):1449-55. PubMed ID: 20845089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
